Rapid amplification of cDNA ends (RACE) is a convenient way to isolate a specific cDNA without building a phage library. RACE kits are available commercially but are expensive and may not capture rare transcripts. We describe a method for isolating 5 ′ RACE clones based on Step-out PCR (7) using Molony murine leukemia virus reverse transcriptase (MMLV-RT) and controlled ribo-tailing (8) . MMLV-RT (e.g., S UPER S CRIPT ™ II; Life Technologies, Rockville, MD, USA) can add a few nontemplate nucleotides (generally 3 or 4 Cs) to the 3 ′ end of newly synthesized first-strand cDNAs (1, 7, 9) . This terminal transferase activity is strongly dependent on the 5 ′ end of mRNA (1, 9) . Furthermore, MMLV-RT has "template switching" activity, meaning that it can switch from transcribing a strand of mRNA to transcribing an appropriate oligonucleotide, thereby extending cDNA synthesis to include a specific sequence (1, 10) . The template switching oligonucleotide (TSO) is designed to be complementary to the newly added Cs on the 3 ′ end of the first-strand cDNA and can have PCR priming and restriction endonuclease sites. These properties of MMLV-RT make it possible to engineer a common priming site at the 5 ′ end of a collection of first-strand cDNAs. A general primer compatible with the TSO is used with gene-specific primers (GSPs) to amplify 5 ′ cDNA ends. Based on these features of MMLV-RT, protocols such as Step-out (7) and CapSelect (9) PCR have been developed for 5 ′ RACE.
For CapSelect PCR, the first-strand cDNA is synthesized, tailed with ribonucleotide and then ligated to an adaptor oligonucleotide.
Step-out PCR exploits the template switching activity of MMLV-RT by adding the TSO to the first-strand cDNA synthesis reaction. Although using a single step to create cDNAs with a common 5 ′ end is efficient, there is a practical difficulty with
Step-out PCR. To get template switching, the TSO has a ribo-G tail that can base pair with the newly added Cs on the first-strand cDNA. The TSO in commercial RACE kits typically contains three ribo-Gs that can rescue only a portion of first-strand cDNAs because MMLV-RT terminal transferase activity is not uniform (9) . We describe a method of ribotailing custom DNA oligonucleotides to generate TSOs that are suitable for use in Step-out PCR. Nonspecific amplification was suppressed using a carrier oligonucleotide (7) .
The Aspergillus nidulanscell morphogenesis gene, hypA , was identified by Kaminskyj and Hamer (5) . The genomic region of hypA contains two open reading frames (ORFs) with a possible intron between them (GenBank ® accession no. AF001273). To clarify this, hypAcDNA was screened for in three cDNA libraries, but this was unsuccessful, which was consistent with hypAhaving a 5.4-kb low-abundance message (not shown). We decided to isolate hypA cDNA clones using 5 ′ RACE. RNA was isolated from A. nidulansvegetative mycelium using Tri Reagent ® (Molecular Research Center, Cincinnati, OH, USA) or Oligotex ™ (Qiagen, Valencia, CA, USA) and treated with DNase I (Amersham Pharmacia Biotech, Piscataway, NJ, USA). 5 ′ RACE, using two different commercial kits, did not give a clonable product, even with recently devised optimization strategies (e.g., see Reference 6). We reasoned that rare messages might be amplified if we modified aspects of the RACE procedure as described below.
We adapted the controlled ribonucleotide tailing method of Schmidt and Mueller (8) using terminal deoxynucleotidyl transferase (TdT) and rGTP to ribo-tail, a custom DNA oligonucleotide (5 ′ -TTACCACTCATGCTTCGGAGA-CTAGCG-3 ′ ), creating the TSO. When designing the TSO, it was important to ensure that its 3 ′ end could not form a hairpin loop that would reduce ribotailing efficiency. Ribo-tailing with TdT is self-limited (mostly 2-4 nucleotides) and greater than 98% efficient (7) . A collection of TSOs tailed with different numbers of ribo-Gs is more likely to rescue cDNAs that have three First-strand cDNA synthesis used S UPER S CRIPT II essentially as described by the manufacturer, except that MgCl 2 concentration was raised to 6 mM from the original 3 mM in supplied buffer. Briefly, 10 pmol gene-specific 5 ′ hypA cDNA synthesis primer (CSP; 5 ′ -CAC -CTCACAGGAGAACG-3 ′ ) was mixed with 5 µ g RNA, and the volume was brought to 10 µ L with water. After denaturing at 70°C for 10 min, the mixture was chilled on ice for 5 min, and the condensate was collected by a brief centrifugation for 1-2 s at 1000 rpm. We was allowed to proceed at 42°C for 60 min and then was stopped by a 10-min heat inactivation at 70°C. This reaction was diluted fivefold in water before PCR amplification.
TSO made with either kind of TdT buffer (original with Co 2+ or self-made with Mg 2+ ) worked well for cDNA synthesis (not shown), but they did not perform equally in 5 ′ RACE. Co 2+ inhibits Taq DNA polymerase (Reference 3 and this study, not shown), whereas cDNA from TSO ribo-tailed in Mg 2+ -TdT buffer resulted in higher nonspecific amplification. For optimum results, we used a TSO that had been ribo-tailed in Co 2+ -containing buffer and desalted before cDNA synthesis ( Figure 1A ). The Co 2+ -buffered tailing reaction was transferred to a Microcon YM-3 (3000 Da mwco; Millipore, Mississauga, ON, Canada) and centrifuged at 14 000 × guntil less than 10 µ L retentate remained, approximately 1 h. The retentate was washed twice by adding 600 µ L RNase-free water to the YM-3, and spinning again until about 10 µ L remained, approximately 2 h per wash. The final product was brought up to 25 µ L with RNase-free water.
5 ′ RACE amplification used touchdown PCR (2,4) with slight modifications. A 50-µ L PCR contained 1.25 U Platinum PfxDNA polymerase (Life Technologies
One microliter of fivefold diluted first-strand cDNA or tenfold diluted first-round PCR product was used as template. Suppression of nonspecific amplification in first-round PCR used 0.02 µ M of the carrier oligonucleotide (7), PA5-CO (5 ′ -GCTCTAG -AGCGGGTGAGCATGATTACCACT -CATGCTTCGGAGACTA-3 ′ ). Various concentrations of PA5-CO were tested for second-round PCR ( Figure 1B) . To prevent degradation of PA5, PA5-CO, GSP1 and GSP2 by the proofreading activity of Platinum PfxDNA polymerase, these primers were modified by having the 3 ′ nucleotide attached with a nonhydrolyzable phosphorothioate ester (Cortec Laboratories, Kingston, ON, Canada).
Our 5 ′ RACE amplification touchdown regime was one cycle of 2.5 min at 94°C; one cycle of 0.5 min at 92°C and 3 min at 70°C; two cycles of 0.5 min at 92°C and 3 min at 68°C; three cycles of 0.5 min at 92°C, 1 min at 67°C and 3 min at 68°C; four cycles of 0.5 min at 92°C, 1 min at 66°C and 3 min at 68°C; five cycles of 0.5 min at 92°C, 1 min at 65°C and 3 min at 68°C; four cycles of 0.5 min at 92°C, 1 min at Benchmarks 64°C and 3 min at 68°C; three cycles of 0.5 min at 92°C, 1 min at 63°C and 3 min at 68°C; twenty cycles of 0.5 min at 92°C, 1 min at 65°C and 3 min at 68°C, programmed on a Hybaid Omn-E thermal cycler (InterScience, Markham, ON, Canada).
First-round amplification using PA5, PA5-CO and GSP1 gave multiple bands, including a doublet that was close to the expected size ( Figure 1A, arrow) , requiring that we use seminested PCR to isolate the proper band. Using PA5 and GSP2 alone to reamplify the first-round product did not reduce the band complexity. However, using 0.2 µ M each PA5-CO, PA5, and GSP2 ( Figure 1B , lane 0.2), the expected 1.8-kb band (Figure 1B, arrow) was strongly amplified.
Comparison with lower concentrations of PA5-CO ( Figure 1B , lanes 0.02-0.1) showed that this was a single band rather than the doublet seen after firstround PCR ( Figure 1A ). This product was gel-purified and cloned and confirmed by restriction enzyme analysis.
Sequencing showed that hypAcontains a 57-bp in-frame intron, which removes the two stop codons after message maturation. The hypAtranslation start site is presumed to be the first ATG in the ORF, although this has yet to be confirmed by expression and Nterminal sequencing of the gene product; the predicted peptide has methionine at the first and twentieth residues. Consistent with this, there is a TATAA site at -12 in the genomic sequence and a CCAAT site at -108.
